Psilocybin mushroom ingestion is classified as a neurotoxic mushroom poisoning syndrome (Group 2A) caused by psilocybin/psilocin, which acts as a partial agonist at serotonin 5-HT2A receptors. [1] Effects are typically self-limited (4–6 hours), and most patients require only supportive care in the ED. [2-3] The critical ED task is distinguishing psilocybin ingestion from potentially lethal mushroom species (e.g., amatoxin-containing mushrooms).
1. History
- What was ingested? Wild-foraged vs. purchased product (chocolate bars, capsules, dried mushrooms); species identification if possible [4]
- How much? Dose is highly variable — potency differs across species and even within the same batch; users frequently underestimate dose [2]
- When? Onset of symptoms relative to ingestion is the single most important historical feature:
- Psilocybin: onset <2 hours (typically 20–60 min) [1][5]
- Amatoxin: onset 6–12 hours (delayed GI symptoms = red flag) [6]
- Co-ingestants? Cannabis, alcohol, MDMA, other drugs are commonly co-ingested; ask about mushroom-containing chocolate products, which may contain adulterants [2][4]
- Psychiatric history? Prior psychosis, bipolar disorder, PTSD, depression — these increase risk of severe psychological adverse events [2][7]
- Current medications? SSRIs, MAOIs, lithium, amphetamines [8-9]
- Intent? Recreational, self-treatment, accidental (foraging misidentification), suicidal
2. Alarm Features
- Delayed symptom onset (>6 hours post-ingestion) — suggests amatoxin or orellanine poisoning, not psilocybin [6][10]
- Severe GI symptoms (profuse watery diarrhea, cholera-like illness) — amatoxin until proven otherwise [6]
- Hyperthermia >40°C, rigidity, clonus — consider serotonin syndrome, especially with co-ingestants or MAOI use [8][11]
- Seizures — rare with psilocybin alone; reported infrequently in poison center data [3-4]
- Hypertensive emergency — reported with MAOI co-administration (phenylethylamine in mushrooms may interact with MAOIs) [9]
- Myocardial injury — troponin elevation has been documented in case series [5]
- Persistent psychosis or severe agitation unresponsive to reassurance
- Suicidal ideation or self-harm — emerging signal, particularly in patients with underlying depression [7]
3. Medications
- Relevant contributors:
- MAOIs + psilocybin mushrooms → risk of hypertensive emergency (phenylethylamine content in mushrooms) [9]
- SSRIs → may attenuate psilocybin effects but rare reports of serotonin toxicity; overall considered low risk without MAOI involvement [8][12]
- Lithium → anecdotal reports of seizures when combined with psychedelics
- Common ED treatments:
- Benzodiazepines (first-line): lorazepam 1–2 mg IV/IM or diazepam 5–10 mg PO/IV for agitation, anxiety, or seizures [4][13-14]
- IV fluids — most common intervention in poison center data (50% of cases) [4]
- Antihypertensives if needed: oral nifedipine 10 mg or IV labetalol [13]
- Contraindicated/caution:
- Avoid antipsychotics as first-line for isolated psilocybin toxicity — benzodiazepines preferred; antipsychotics (olanzapine 5–10 mg, risperidone) reserved for refractory psychosis [13]
- Flumazenil — not indicated
- No specific antidote exists for psilocybin
4. Diet
- Not a major clinical consideration in acute management
- Patients may present with nausea/vomiting — NPO until mental status clears
- Hydration is important, especially if vomiting or prolonged agitation
- Anecdotal reports suggest ginger may potentiate serotonergic effects — caution advised [13]
5. Review of Systems
- Neuro/Psych: Hallucinations (visual > auditory), paranoia, anxiety, euphoria, depersonalization, time distortion, confusion [3][15]
- GI: Nausea, vomiting, abdominal discomfort (common, usually mild) [13]
- CV: Palpitations, chest pain (rare but reported) [5]
- MSK: Muscle tension, paresthesias [16]
- Constitutional: Dizziness, fatigue, headache [13]
6. Collateral History and Family History
- Collateral from friends/bystanders is essential — patient may be unable to provide reliable history during acute intoxication
- Determine: what was taken, how much, when, any other substances, any prior similar episodes
- Family history of psychotic disorders (schizophrenia, bipolar) — increases risk of unmasking psychosis [7]
- Social context: setting of use, supervision, access to additional substances
7. Risk Factors
- Age: Predominantly adolescents and young adults (83.9% aged 13–29) [3]
- Sex: ~78% male [3][15]
- Psychiatric vulnerability: Pre-existing depression, anxiety, psychotic spectrum disorders, PTSD [2][7]
- Polydrug use: Cannabis, alcohol, MDMA co-ingestion common and increases adverse event severity [2][17]
- Wild foraging: Risk of misidentification with lethal species [5][10]
- Unregulated products: Mushroom-containing chocolates may have variable potency or adulterants [4]
- MAOI use: Specific risk for hypertensive crisis [9]
8. Differential Diagnosis
The critical differential centers on ruling out dangerous mushroom ingestions and other toxidromes:
- Amatoxin poisoning (Amanita phalloides) — delayed GI onset (6–12 h), followed by hepatorenal failure; 90% of mushroom fatalities. Key differentiator: timing of symptom onset [6][10]
- Muscarine poisoning — cholinergic toxidrome (SLUDGE: salivation, lacrimation, urination, diarrhea, GI distress, emesis), miosis, bradycardia [1]
- Ibotenic acid/muscimol (Amanita muscaria) — CNS depression, ataxia, delirium, seizures; anticholinergic features [1]
- Serotonin syndrome — clonus, hyperthermia, rigidity, hyperreflexia; especially with MAOI/SSRI co-ingestion [8][11]
- Sympathomimetic toxidrome — amphetamines, synthetic cathinones, cocaine
- Anticholinergic toxidrome — dry, flushed skin, urinary retention, mydriasis, absent bowel sounds
- Acute psychosis (primary psychiatric) — no clear temporal relationship to ingestion
- Gyromitrin poisoning — delayed onset, hepatotoxicity, seizures, methemoglobinemia [1]
9. Past Medical History
- Psychiatric disorders: Bipolar disorder, schizophrenia, major depression — higher risk of severe psychological adverse events and suicidality [7]
- Cardiovascular disease: Hypertension, coronary artery disease — psilocybin causes transient BP and HR elevation [5][13]
- Prior psychedelic use: Tolerance develops rapidly; prior "bad trips" predict recurrence
- Substance use disorders
- Hepatic/renal disease — psilocin is hepatically metabolized and renally excreted [2]
10. Physical Exam
- Vitals: Tachycardia (18–76% of cases), hypertension (common, usually mild-moderate; SBP >150 reported), hyperthermia (rare but serious) [3][5][13]
- Eyes: Mydriasis (dilated pupils) — hallmark finding
- Neuro: Altered mental status, agitation, hyperreflexia, ataxia, nystagmus; assess for clonus and rigidity (serotonin syndrome)
- Skin: Diaphoresis, flushing; check for dry skin (anticholinergic mimic)
- Abdomen: Mild tenderness possible; assess bowel sounds
- Psych: Assess for hallucinations, paranoia, suicidal ideation, capacity for self-harm
11. Lab Studies
Labs are primarily to rule out dangerous co-ingestions and complications, not to confirm psilocybin (no routine clinical assay exists):
- Point-of-care glucose — rule out hypoglycemia as cause of altered mental status [14]
- BMP/CMP — electrolytes, renal function, hepatic function
- LFTs (AST/ALT) — critical to rule out amatoxin hepatotoxicity if any concern for wild mushroom misidentification [6][18]
- Troponin — if chest pain, severe hypertension, or ECG changes [5]
- CK — if prolonged agitation, rigidity, or concern for rhabdomyolysis [5]
- Urine drug screen — will NOT detect psilocybin; useful to identify co-ingestants (amphetamines, PCP, cannabis)
- Coagulation studies (PT/INR) — if concern for amatoxin ingestion [18]
- Lactate — if hemodynamically unstable or hyperthermic
- Serum acetaminophen, salicylate levels — standard in undifferentiated ingestion
12. Imaging
- Generally unnecessary for isolated psilocybin ingestion
- CT head — consider if: trauma suspected (falls during intoxication), focal neurological deficits, seizures, or altered mental status not improving as expected
- Chest X-ray — if respiratory distress or aspiration concern
- No gold standard imaging specific to psilocybin toxicity
13. Special Tests
- Poison Control consultation (800-222-1222) — recommended for all mushroom ingestions, especially wild-foraged [10][14]
- Mycologist consultation — if mushroom remnants or photos available for species identification [10]
- Hunter-Sternbach criteria or Boyer criteria for serotonin syndrome if suspected [11]
- No routine clinical assay for psilocybin/psilocin — EDs rarely test for psychedelics [2]
- Amatoxin urine assay — available at some centers if amatoxin ingestion suspected
14. ECG
- Obtain ECG if: chest pain, palpitations, severe hypertension, co-ingestion with stimulants, or MAOI use
- Expected findings: Sinus tachycardia (most common)
- Dangerous patterns to recognize:
- ST-segment changes — ST elevation reported in a case of psilocybin + MAOI + amphetamine combination [9]
- Dysrhythmias reported in 19% of mushroom-chocolate exposures [4]
- QTc prolongation — consider if co-ingested with QT-prolonging agents
15. Assessment
- Typical presentation: Young male with acute onset (within 1–2 hours of ingestion) of visual hallucinations, agitation, mydriasis, tachycardia, and mild nausea, with self-limited course over 4–6 hours [2-3][15]
- Severity stratification:
- Mild: Euphoria, mild perceptual changes, nausea — observation only
- Moderate: Significant agitation, paranoia, anxiety, tachycardia, hypertension — benzodiazepines, IV fluids [3-4]
- Severe (rare): Hyperthermia, seizures, coma, hypertensive emergency, myocardial injury, psychosis [3][5][9]
- Atypical presentations: Delayed onset (consider wrong mushroom), isolated GI symptoms, cardiovascular complications, persistent psychosis
- Complications: Trauma from impaired judgment, aspiration, rhabdomyolysis (rare), HPPD (rare, long-term) [2-3]
16. Treatment Plan
Initial stabilization
- ABCs; protect airway if severely obtunded
- Place in calm, low-stimulation environment with 1:1 observation
- Verbal de-escalation and reassurance first ("talk-down")
Pharmacologic management
- Agitation/anxiety/panic: Benzodiazepines — lorazepam 1–2 mg IV/IM or diazepam 5–10 mg PO/IV; repeat as needed [4][13-14]
- Nausea/vomiting: Ondansetron 4 mg IV; IV fluids for hydration [4]
- Hypertension: Oral nifedipine 10–20 mg or IV labetalol if sustained/severe [13]
- Seizures: Benzodiazepines first-line [14]
- Serotonin syndrome: Discontinue serotonergic agents, aggressive cooling, benzodiazepines; cyproheptadine 12 mg PO loading then 2 mg q2h for moderate-severe cases [8][11]
- Refractory psychosis: Olanzapine 5–10 mg IM or risperidone PO as second-line [13]
Decontamination
- Activated charcoal generally not indicated for isolated psilocybin (rapid absorption, benign course)
- Consider if co-ingestion with dangerous substance or if wild mushroom identity uncertain and amatoxin cannot be excluded [6]
17. Disposition
- Discharge criteria: Most patients can be treated and released from the ED once symptoms resolve (typically 4–6 hours), mental status returns to baseline, vital signs normalize, and patient is not suicidal [2-3]
- Observation: Patients with persistent symptoms, polydrug ingestion, or psychiatric comorbidities
- Admission criteria:
- Persistent altered mental status beyond 6–8 hours
- Hemodynamic instability, hyperthermia, seizures
- Concern for amatoxin ingestion (obtain serial LFTs at 12–24 hours) [6]
- Suicidal ideation or psychosis requiring psychiatric evaluation [2]
- Myocardial injury (troponin elevation) [5]
- Critical care: Serotonin syndrome, hypertensive emergency, status epilepticus
- Specialist consultation triggers: Toxicology, psychiatry, hepatology (if amatoxin concern), cardiology (if myocardial injury)
- Poison center data show ~66% treated and released, ~15% admitted [2]
18. Follow Up / Return Precautions
- Return immediately for: Recurrence of hallucinations or confusion, severe headache, abdominal pain, jaundice (could indicate missed amatoxin exposure), chest pain, suicidal thoughts, or any new neurological symptoms
- Follow-up timing: Primary care or psychiatry within 1–2 weeks if psychiatric symptoms persist
- HPPD monitoring: Rare but persistent visual disturbances (flashbacks, visual snow) may develop days to weeks later — refer to psychiatry if impairing [2][13]
- Counseling points:
- Effects are self-limited and will resolve
- Warn about risk of HPPD with repeated use
- Discuss dangers of wild mushroom foraging and misidentification [5][10]
- Substance use counseling and harm reduction as appropriate
- Expected recovery: Full resolution within 24–48 hours for the vast majority; headache and fatigue may persist 1–2 days [13]
References
1. Mushroom Poisoning: A Proposed New Clinical Classification. — White J, Weinstein SA, De Haro L, et al. Toxicon : Official Journal of the International Society on Toxinology. 2019.
2. Psilocybin Outside the Clinic. — Hutchison KE, Hooper JF, Karoly HC. JAMA Psychiatry. 2025.
3. Does Getting High Hurt? Characterization of Cases of LSD and Psilocybin-Containing Mushroom Exposures to National Poison Centers Between 2000 and 2016. — Leonard JB, Anderson B, Klein-Schwartz W. Journal of Psychopharmacology. 2018.
4. Psychedelic Mushroom-Containing Chocolate Exposures: Case Series. — Gartner HT, Wan HZ, Simmons RE, Sollee DR, Sheikh S. The American Journal of Emergency Medicine. 2024.
5. Dynamic Myocardial Injury and Variable Hallucination Latency in Psilocybe Keralensis Poisoning: A Molecularly Confirmed Case Series From China. — He Z, Tang R, Feng M, et al. Clinical Toxicology. 2025.
6. Acute Liver Failure Guidelines. — Shingina A, Mukhtar N, Wakim-Fleming J, et al. The American Journal of Gastroenterology. 2023.
7. Considerations and Cautions for the Integration of Psilocybin Into Routine Clinical Care: A Consensus Statement From the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds. — Hosein MM, Reid MJ, Walser S, et al. EClinicalMedicine. 2025.
8. Serotonin Toxicity of Serotonergic Psychedelics. — Malcolm B, Thomas K. Psychopharmacology. 2022.
9. Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine. — Barnett BS, Koons CJ, Van den Eynde V, Gillman PK, Bodkin JA. Journal of Psychoactive Drugs. 2025.
10. Mushroom Poisoning. — Wennig R, Eyer F, Schaper A, Zilker T, Andresen-Streichert H. Deutsches Arzteblatt International. 2020.
11. Serotonin Syndrome-a Focused Review. — Mikkelsen N, Damkier P, Pedersen SA. Basic & Clinical Pharmacology & Toxicology. 2023.
12. Content Analysis of Reddit Posts About Coadministration of Selective Serotonin Reuptake Inhibitors and Psilocybin Mushrooms. — Sakai K, Bradley ER, Zamaria JA, et al. Psychopharmacology. 2024.
13. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. — Yerubandi A, Thomas JE, Bhuiya NMMA, et al. JAMA Network Open. 2024.
14. Acute Medication Poisoning. — Vega IL, Griswold MK, Laskey D. American Family Physician. 2024.
15. Hallucinogenic Mushroom Misuse Reported to Texas Poison Centers. — Forrester MB. Journal of Addictive Diseases. 2020.
16. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression. — Mertens LJ, Koslowski M, Betzler F, et al. JAMA Psychiatry. 2026.
17. Clinical Effects of Psychedelic Substances Reported to United States Poison Centers: 2012 to 2022. — Simon MW, Olsen HA, Hoyte CO, et al. Annals of Emergency Medicine. 2024.
18. From Liver Injury to Failure: Identification of Predictive Biomarkers in Suspected Amatoxin-Containing Mushroom Poisoning-a Retrospective Case Analysis. — Ma X, Zhou W, Bu B, et al. Toxicon : Official Journal of the International Society on Toxinology. 2025.